Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Equity Ratio (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Equity Ratio for 16 consecutive years, with 0.65 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 26.08% to 0.65 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.65 through Dec 2025, down 26.08% year-over-year, with the annual reading at 0.65 for FY2025, 26.08% down from the prior year.
  • Equity Ratio hit 0.65 in Q4 2025 for Ligand Pharmaceuticals, up from 0.64 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.89 in Q2 2024 to a low of 0.58 in Q1 2021.
  • Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.79 in 2023.
  • Biggest five-year swings in Equity Ratio: grew 24.63% in 2022 and later decreased 26.96% in 2025.
  • Year by year, Equity Ratio stood at 0.63 in 2021, then grew by 23.79% to 0.78 in 2022, then increased by 13.65% to 0.89 in 2023, then decreased by 0.96% to 0.88 in 2024, then decreased by 26.08% to 0.65 in 2025.
  • Business Quant data shows Equity Ratio for LGNDZ at 0.65 in Q4 2025, 0.64 in Q3 2025, and 0.87 in Q2 2025.